HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Clinical trials for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER explained in plain language.
Never miss a new study
Get alerted when new HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER trials appear
Sign up with your email to follow new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bladder cancer drug enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called JL19001, given alone or with standard BCG therapy, in 18 people with high-risk non-muscle invasive bladder cancer. The main goals are to check safety, find the right dose, and see how the body handles the drug. It's a first step to s…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Targeted bladder cancer drug takes on chemo in Late-Stage trial
Disease control Recruiting nowThis phase 3 trial tests a new drug, TAR-210 (erdafitinib), placed directly into the bladder, against standard chemotherapy for people with a high-risk type of bladder cancer that has come back after BCG treatment. The study includes 220 adults whose tumors have certain FGFR gene…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Bladder-Sparing hope: immune combo targets tough bladder cancer
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (toripalimab) to standard BCG therapy can help people with high-risk bladder cancer avoid bladder removal. About 31 participants will receive the combination after surgery. The main goal is to see if the cancer disappears with…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug combo aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study tests whether adding the drug disitamab vedotin to standard BCG therapy can help keep high-risk, early-stage bladder cancer from returning. It includes 182 adults whose cancer has been surgically removed but is at high risk of coming back. Participants will receive eit…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New bladder cancer drug shows promise in early trial
Disease control Recruiting nowThis study tests a new drug called MK-3120 for high-risk non-muscle invasive bladder cancer. After standard tumor removal, 45 participants will receive the drug directly into the bladder. The main goals are to check safety and how well people tolerate it, while also looking at tu…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New vaccine-like therapy aims to keep bladder cancer from coming back
Disease control Recruiting nowThis study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo aims to fight bladder cancer when standard treatment fails
Disease control Recruiting nowThis phase 2 trial tests a two-drug combination (mitomycin-C and gemcitabine) given directly into the bladder for people with high-risk bladder cancer that did not respond to BCG therapy. The study will enroll 82 participants to see if this sequential treatment can prevent cancer…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo offers hope for bladder cancer patients who failed standard therapy
Disease control Recruiting nowThis study tests a new treatment for people with a high-risk type of bladder cancer that did not get better after standard BCG therapy. The treatment combines two chemotherapy drugs placed directly into the bladder with an immunotherapy drug given through a vein. The goal is to s…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: BLATAM • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
Bladder cancer virus therapy shows promise in Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial tests a drug called cretostimogene grenadenorepvec in 325 people with high-risk non-muscle-invasive bladder cancer. The drug is a virus that is put directly into the bladder to attack cancer cells. The study looks at how well it works and how safe it is, includ…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: PHASE2 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Freeze, then boost: novel combo could spare bladders from removal
Disease control Recruiting nowThis study tests a new approach to treat high-risk bladder cancer without removing the bladder. Doctors will first remove the tumor through the urethra, then freeze the tumor base with a special balloon, followed by immunotherapy and low-dose chemotherapy. The goal is to see if t…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: NA • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Pee test could replace painful bladder scopes for cancer patients
Diagnosis Recruiting nowThis study is testing whether a simple urine test that looks for cancer DNA can help decide when patients with high-risk bladder cancer need a cystoscopy (a camera exam of the bladder). Cystoscopy is effective but uncomfortable and can cause infections. The goal is to safely redu…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Phase: NA • Sponsor: Tianjin Medical University Second Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Urine test may spare bladder cancer patients from unnecessary second surgery
Diagnosis Recruiting nowThis study looks at whether a simple urine test can detect leftover cancer after initial surgery for high-risk bladder cancer. The goal is to help doctors decide who truly needs a second surgery, avoiding unnecessary procedures and their risks. About 60 adults with high-risk non-…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Sponsor: Tianjin Medical University Second Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
Could a simple blood or urine test spot bladder cancer earlier?
Knowledge-focused Recruiting nowThis study is collecting blood, urine, and tumor tissue samples from about 400 adults with suspected high-risk non-muscle invasive bladder cancer. The goal is to find biological markers that could lead to new tests for detecting and monitoring this type of cancer. Participants wi…
Matched conditions: HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
Sponsor: Natera, Inc. • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC